Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Acquired Hemophilia

What is Acquired Hemophilia?

Acquired hemophilia (AH) is an autoimmune disorder that affects the normal functioning of coagulation factors and prevents the blood from clotting. An autoimmune disease describes when the body’s immune system targets important processes or tissues and causes harm to itself. The immune system releases antibodies that target foreign substances called antigens to mark them for destruction by the body. Autoantibodies are antibodies that target something created in the body and can disrupt normal processes. Individuals with acquired hemophilia produce autoantibodies, also known as inhibitors, that target and destroy coagulation factor VIII, or inhibit blood clotting. Coagulation factor VIII (FVIII) is a protein that is crucial for the factor IXa to function and activate factor X, which generates thrombin and begins the process of blood clotting to prevent hemorrhaging. Loss of function of factor VIII poses high risk to the individual as their clotting factors will no longer be able to repair damaged tissue, causing them to bleed without stopping. This uncontrolled bleeding can occur in the muscles, skin, and soft tissue following injury or surgery. 

Congenital hemophilia differs from acquired hemophilia as it is caused by a genetic mutation and not a dysfunction of the body’s immune system. While the cause and bleeding pattern is different from congenital hemophilia, the lack of clotting factor VIII is the same. However, both rare diseases have different treatment options. 

 

Synonyms

  • Acquired Hemophilia A
  • Acquired Hemophilia B

Acquired hemophilia (AH) is an autoimmune disorder that affects the normal functioning of coagulation factors and prevents the blood from clotting. An autoimmune disease describes when the body’s immune system targets important processes or tissues and causes harm to itself. The immune system releases antibodies that target foreign substances called antigens to mark them for destruction by the body. Autoantibodies are antibodies that target something created in the body and can disrupt normal processes. Individuals with acquired hemophilia produce autoantibodies, also known as inhibitors, that target and destroy coagulation factor VIII, or inhibit blood clotting. Coagulation factor VIII (FVIII) is a protein that is crucial for the factor IXa to function and activate factor X, which generates thrombin and begins the process of blood clotting to prevent hemorrhaging. Loss of function of factor VIII poses high risk to the individual as their clotting factors will no longer be able to repair damaged tissue, causing them to bleed without stopping. This uncontrolled bleeding can occur in the muscles, skin, and soft tissue following injury or surgery. 

Congenital hemophilia differs from acquired hemophilia as it is caused by a genetic mutation and not a dysfunction of the body’s immune system. While the cause and bleeding pattern is different from congenital hemophilia, the lack of clotting factor VIII is the same. However, both rare diseases have different treatment options. 

Acknowledgement of Acquired Hemophilia has not been added yet.

There are about 1.5 individuals per million people that are diagnosed with acquired hemophilia every year. Acquired hemophilia can affect men and women of all ethnicities and backgrounds with equal prevalence, however the risk increases with age and the development of other autoimmune disorders. About 50% of AH cases are caused by an underlying autoimmune condition, while the other 50% have an unknown cause. About ⅓ of individuals diagnosed with AH will not require treatment to control their bleeding, but another ⅓ of individuals will suffer multiple bleeding episodes. There are also about 1-5% of cases of AH reported in women during or following pregnancy (postpartum period) wherein they develop severe bleeding episodes.

Name Abbreviation
Acquired Hemophilia A AHA
Acquired Hemophilia B AHB

The rare disease acquired hemophilia (AH) is caused by the body’s immune system producing autoantibodies that target clotting factors instead of foreign antigens for degradation or destruction. The reduction of properly functioning clotting factors prevents blood from clotting aat crucial damaged sites within the body. Individuals with a reduced efficiency of clotting factor VIII have acquired hemophilia A, while those with reduced efficiency of clotting factor IX have the much more rare form of acquired hemophilia B. About 50% of individuals with AH acquired the disorder due to another autoimmune disorder or immune-triggering event that produced autoantibodies that began targeting their clotting factors. These autoimmune disorders include lupus, rheumatoid arthritis, multiple sclerosis, Sjogren syndrome, temporal arteritis, IBS, ulcerative colitis, infection, diabetes, hepatitis, respiratory or dermatological diseases, blood cancer or certain solid tumors. In some cases, a prescribed therapeutic such as penicillin or interferons have been associated with an individual’s development of acquired hemophilia. Additionally, some women have been diagnosed with AH during pregnancy or postpartum if they develop episodes of severe bleeding with no other known cause.

There are different types and locations that may be affected by acquired hemophilia and thus prone to uncontrolled bleeding. These types of bleeding may include subcutaneous (ecchymoses) as the most common, muscle bleeding (hematoma), gastrointestinal (melena), genitourinary (hematuria), retroperitoneal, intracranial hemorrhage (rare but fatal), and while rare some cases of joint bleeding (hemarthrosis) which is more common in individuals with congenital hemophilia. These symptoms of uncontrolled bleeding may cause compartment syndrome in the soft tissue, pressure exerted on the muscles, nerves, and blood vessels that may cause other complications. Signs of this uncontrolled bleeding that an individual should be aware of are developments of nosebleeds (epistaxis), bruising, solid swelling of congealed blood deposits (hematomas), blood in urine (hematuria), and gastrointestinal or urogenital bleeding.

A clinician may test for acquired hemophilia following initial inspection of an individual with abnormal bleeding, especially if the person is elderly (between 60-80 years old) or a woman in postpartum period. Reports of the signs and symptoms may also prompt testing for a diagnosis of AH. 

 

The diagnostic tests for acquired hemophilia require determining that the uncontrolled bleeding is due to lack of clotting factor VIII, and that this decrease in clotting factors is due to high levels of autoantibodies targeting FVIII. The following is a list of tests and explanations about how they establish AH and rule out other causes:

  1. Coagulation tests aPTT and PT - The measurement of the coagulation time of the blood can be achieved using activated partial thromboplastin time (aPTT) and/or prothrombin time (PT). aPPT is dependent on the proper functioning of factors VIII, IX, XI< and XII and thus tests for AHA, while PT is dependent on factors II, VII, and IX and thus tests for AHB. A 25-35% reduction of factor VIII will cause a noticeable change in aPTT time and is typical of a diagnosis of AHA. 

  2. aPTT mixing test - An individual’s blood can be mixed with a sample of a healthy person’s blood that contains the proper clotting factors. If the aPTT time decreases (blood clots faster than patient’s blood alone), then the disorder is due to a lack of coagulation factors and can be corrected with the addition of coagulation factors (congenital hemophilia or other disorder). If, however, the coagulation time does not improve, the disorder is due to factor inhibitors actively decreasing the amount of FVIII in the blood (acquired hemophilia).

  3. Titer count of factor inhibitors present in the blood determines the overall concentration and severity of the disease

  4. Bethesda assay - Developed to determine the amount of VIII autoantibodies in the blood, the Bethesda assay defines a unit of Bethesda unit (BU) that indicates the amount of inhibiting autoantibodies that are needed to destroy 50% of a sample of factor VIII. 

Treatment is highly dependent on the individual case due to the differences between acquired and congenital hemophilia, the scarcity of this disease, and also the different symptoms that may be experienced by the individual. These different symptoms may be due to the possible underlying cause of the acquired disorder, the age of the individual, tolerance and/or allergies to certain treatments, and other factors that must be considered before providing care. The three main goals in treatment strategies for acquired hemophilia are the management of bleeding, the elimination of inhibiting antibodies that target the coagulation factors, and treating any underlying diseases that may have caused the autoimmune response.

  1. Bleeding management – Anti-hemorrhagic treatments such as bypassing agents or increased concentration of coagulation factors (often VIII) may be administered at the site of heavy bleeding. Bypassing agents are recombinantly (synthetically) produced factor VII proteins that replace those attacked by autoimmune function, including rFVIIa, NovoSeven® RT, or Sevenfact. Activated prothrombin complex concentrate (aPCC) is a complex composed of clotting factors that are already activated and do not require factor VIII, often depleted in the presence of inhibiting autoantibodies.

  2. Elimination of Inhibitors – This is often a form of immunosuppressive therapy aimed to deplete the autoantibodies targeting and destroying coagulation factors. One common treatment combination is corticosteroids with cyclophosphamide, but due to different individuals’ responses to immunosuppressive treatments others are available such as cyclosporine A, azathioprine, vincristine, mycophenolate mofetil, and 2-chlorodeoxyadenosine. Plasmapheresis can also be implemented to replace an individual’s plasma containing autoantibodies with a healthy person’s plasma that contains normal levels of coagulation factors and no autoantibodies.

  3. Treatment of other disorders – Rituximab is currently being studied for its efficacy in targeting autoantibodies in individuals with many autoimmune diseases, including acquired hemophilia.

Cases of acquired hemophilia vary in their symptoms and severity from person to person. Often, the prognosis of the individual is also dependent on other factors, such as age of onset, other autoimmune disorders that may have caused the inhibition of coagulation factors, and the affected tissues that are prone to uncontrolled bleeding. Some cases have been reported to improve, such as women experiencing post-partum acquired hemophilia that may go into remission within a few months following their delivery. Additionally, individuals with AH caused by an underlying autoimmune disease can be treated with immunosuppressing agents (IST), with about 60-80% of cases in remission over a period of days to months. These individuals should monitor their symptoms and dosage to prevent reappearance or drug resistance. Individuals on immunosuppressants should also be monitored for signs of infection, a side effect associated with lowering the antibodies capable of responding to foreign agents. Individuals without underlying autoimmune disorders or who do not seek treatment could be subject to severe bleeding episodes and hemorrhaging, which can be life-threatening and fatal if left untreated.

Tips or Suggestions of Acquired Hemophilia has not been added yet.
  1. Haider MZ, Anwer F. Acquired Hemophilia. [Updated 2022 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560494/

  2. Tiede A, Hofbauer CJ, Werwitzke S, Knöbl P, Gottstein S, Scharf RE, Heinz J, Groß J, Holstein K, Dobbelstein C, Scheiflinger F, Koch A, Reipert BM. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood. 2016 May 12;127(19):2289-97. doi: 10.1182/blood-2015-09-672774. Epub 2016 Feb 24. PMID: 26912467.

  3. Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kühne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R, von Auer C, Krause M, Leimkühler K, Kalus U, Blumtritt JM, Werwitzke S, Budde E, Koch A, Knöbl P. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015 Feb 12;125(7):1091-7. doi: 10.1182/blood-2014-07-587089. Epub 2014 Dec 18. PMID: 25525118; PMCID: PMC4326770.

  4. https://rarediseases.org/rare-diseases/acquired-hemophilia/#:~:text=Acquired%20hemophilia%20(AH)%20is%20a,attacks%20healthy%20cells%20or%20tissue.

  5. https://www.ncbi.nlm.nih.gov/books/NBK560494/

  6. https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V19.2.2022214/484175/Autoimmune-Acquired-Hemophilia-Updates-in

  7. https://www.haematologica.org/article/view/9931

Hi is there anyone out there : ) Created by Samrobandolivia
Last updated 28 Jun 2013, 09:43 PM

Posted by Samrobandolivia
28 Jun 2013, 09:43 PM

Hi, I notice this community only has one member, I just wondered if the one member uses this site any more really, thank you.

Community Resources
Title Description Date Link

Clinical Trials


Cords registry

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.

Enrolling is easy.

  1. Complete the screening form.
  2. Review the informed consent.
  3. Answer the permission and data sharing questions.

After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.

Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.

Visit sanfordresearch.org/CoRDS to enroll.

Community Leaders

 

Expert Questions

Ask a question

Community User List

Type 1 diabetic just been diagnosed with Acquired Hemophilia, wanting to know personal experiences.

Start a Community


Don't See Your Condition On Rareshare?

Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.

FAQ


Have questions about rareshare?

Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.

Discussion Forum

Hi is there anyone out there : )

Created by Samrobandolivia | Last updated 28 Jun 2013, 09:43 PM


Communities

Our Communities

Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.

FIND YOUR COMMUNITY
Physicians

Our Resources

Our rare disease resources include e-books and podcasts

VIEW OUR EBOOKS

LISTEN TO OUR PODCASTS

VIEW OUR GUIDES

Leaders

Our Community Leaders

Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.